Total Payments
$468,969
2022 Payments
$554.10
Companies
11
Transactions
333
Medicare Patients
1,138
Medicare Billing
$139,127
Payment Breakdown by Category
Other$314,086 (67.0%)
Consulting$108,196 (23.1%)
Research$23,140 (4.9%)
Travel$16,581 (3.5%)
Food & Beverage$6,954 (1.5%)
Education$12.74 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $292,576 | 119 | 62.4% |
| Consulting Fee | $108,196 | 28 | 23.1% |
| Unspecified | $23,140 | 6 | 4.9% |
| Honoraria | $21,510 | 10 | 4.6% |
| Travel and Lodging | $16,581 | 56 | 3.5% |
| Food and Beverage | $6,954 | 113 | 1.5% |
| Education | $12.74 | 1 | 0.0% |
Payments by Type
General
$445,829
327 transactions
Research
$23,140
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $337,355 | 213 | $0 (2021) |
| Alexion Pharmaceuticals, Inc. | $96,593 | 87 | $0 (2022) |
| CATALYST PHARMACEUTICALS, INC. | $11,998 | 7 | $0 (2021) |
| Alnylam Pharmaceuticals Inc. | $11,854 | 7 | $0 (2021) |
| Genentech, Inc. | $7,955 | 4 | $0 (2020) |
| GENZYME CORPORATION | $2,975 | 2 | $0 (2017) |
| ABBVIE INC. | $161.96 | 9 | $0 (2022) |
| SS White Burs, Inc. | $29.57 | 1 | $0 (2019) |
| PFIZER INC. | $21.75 | 1 | $0 (2017) |
| Mitsubishi Tanabe Pharma America, Inc. | $12.74 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $554.10 | 3 | Alexion Pharmaceuticals, Inc. ($510.00) |
| 2021 | $92,213 | 70 | Biogen, Inc. ($73,458) |
| 2020 | $82,520 | 53 | Biogen, Inc. ($36,798) |
| 2019 | $126,588 | 81 | Biogen, Inc. ($76,150) |
| 2018 | $123,470 | 84 | Biogen, Inc. ($110,333) |
| 2017 | $43,624 | 42 | Biogen, Inc. ($40,615) |
All Payment Transactions
333 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/12/2022 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $16.94 | General |
| Category: NEUROSCIENCE | ||||||
| 05/11/2022 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $510.00 | General |
| Category: Rare Disease | ||||||
| 03/04/2022 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $27.16 | General |
| Category: NEUROSCIENCE | ||||||
| 12/22/2021 | AbbVie Inc. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $17.47 | General |
| Category: NEUROSCIENCE | ||||||
| 12/21/2021 | Alexion Pharmaceuticals, Inc. | Soliris (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $765.00 | General |
| Category: Immunology | ||||||
| 12/20/2021 | Alnylam Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| 12/16/2021 | Biogen, Inc. | SPINRAZA (Biological) | Consulting Fee | Cash or cash equivalent | $3,390.00 | General |
| Category: NEUROLOGY | ||||||
| 12/01/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $11.32 | General |
| Category: NEUROSCIENCE | ||||||
| 11/18/2021 | Biogen, Inc. | SPINRAZA (Biological) | Consulting Fee | Cash or cash equivalent | $2,260.00 | General |
| Category: NEUROLOGY | ||||||
| 11/17/2021 | Biogen, Inc. | SPINRAZA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,130.00 | General |
| Category: NEUROLOGY | ||||||
| 11/03/2021 | Biogen, Inc. | SPINRAZA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,695.00 | General |
| Category: NEUROLOGY | ||||||
| 10/27/2021 | Biogen, Inc. | SPINRAZA (Biological) | Consulting Fee | Cash or cash equivalent | $1,130.00 | General |
| Category: NEUROLOGY | ||||||
| 10/08/2021 | Biogen, Inc. | SPINRAZA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,130.00 | General |
| Category: NEUROLOGY | ||||||
| 09/29/2021 | Biogen, Inc. | SPINRAZA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,130.00 | General |
| Category: NEUROLOGY | ||||||
| 09/24/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $9.27 | General |
| Category: NEUROSCIENCE | ||||||
| 09/21/2021 | Biogen, Inc. | SPINRAZA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,695.00 | General |
| Category: NEUROLOGY | ||||||
| 09/10/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $10.63 | General |
| Category: NEUROSCIENCE | ||||||
| 08/31/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $20.49 | General |
| Category: NEUROSCIENCE | ||||||
| 08/27/2021 | Biogen, Inc. | SPINRAZA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,130.00 | General |
| Category: NEUROLOGY | ||||||
| 08/26/2021 | Biogen, Inc. | SPINRAZA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,367.50 | General |
| Category: NEUROLOGY | ||||||
| 08/25/2021 | Biogen, Inc. | SPINRAZA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,695.00 | General |
| Category: NEUROLOGY | ||||||
| 08/18/2021 | Biogen, Inc. | SPINRAZA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,695.00 | General |
| Category: NEUROLOGY | ||||||
| 07/28/2021 | Biogen, Inc. | SPINRAZA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,695.00 | General |
| Category: NEUROLOGY | ||||||
| 07/26/2021 | Biogen, Inc. | SPINRAZA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,085.00 | General |
| Category: NEUROLOGY | ||||||
| 07/26/2021 | Biogen, Inc. | SPINRAZA (Biological) | Travel and Lodging | Cash or cash equivalent | $745.90 | General |
| Category: NEUROLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis | Alexion Pharmaceuticals, Inc. | $23,140 | 6 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 95 | 99 | $36,503 | $12,389 |
| 2022 | 4 | 76 | 91 | $14,248 | $5,193 |
| 2021 | 12 | 434 | 528 | $261,347 | $58,975 |
| 2020 | 15 | 533 | 639 | $319,992 | $62,570 |
Total Patients
1,138
Total Services
1,357
Medicare Billing
$139,127
Procedure Codes
35
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| G0427 | Telehealth consultation, emergency department or initial inpatient, typically 70 minutes or more communicating with the patient via telehealth | Office | 2023 | 44 | 44 | $22,614 | $7,388 | 32.7% |
| G0426 | Telehealth consultation, emergency department or initial inpatient, typically 50 minutes communicating with the patient via telehealth | Office | 2023 | 24 | 24 | $8,362 | $2,858 | 34.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 16 | 16 | $4,102 | $1,580 | 38.5% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 11 | 15 | $1,425 | $562.80 | 39.5% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 22 | 22 | $4,180 | $1,662 | 39.8% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 16 | 16 | $4,138 | $1,576 | 38.1% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 27 | 36 | $3,550 | $1,028 | 29.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 11 | 17 | $2,380 | $928.06 | 39.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 96 | 124 | $58,900 | $14,907 | 25.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 112 | 151 | $57,833 | $12,610 | 21.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 41 | 54 | $34,614 | $8,558 | 24.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 29 | 29 | $26,651 | $5,910 | 22.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 20 | 20 | $14,720 | $2,974 | 20.2% |
| 95885 | Needle measurement and recording of electrical activity of muscles of arm or leg limited study | Office | 2021 | 37 | 42 | $12,474 | $2,779 | 22.3% |
| 95908 | Nerve transmission studies, 3-4 studies | Office | 2021 | 24 | 25 | $15,200 | $2,773 | 18.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 21 | 21 | $11,655 | $2,667 | 22.9% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 18 | 18 | $7,485 | $1,764 | 23.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 11 | 11 | $6,435 | $1,714 | 26.6% |
| 92610 | Evaluation of swallowing function | Office | 2021 | 12 | 16 | $10,816 | $1,221 | 11.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 13 | 17 | $4,564 | $1,098 | 24.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 86 | 109 | $51,775 | $11,147 | 21.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 94 | 128 | $49,024 | $7,851 | 16.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 53 | 54 | $32,670 | $7,175 | 22.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 40 | 51 | $32,691 | $6,101 | 18.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 34 | 34 | $31,246 | $5,980 | 19.1% |
About Dr. Anthony Geraci, M.D
Dr. Anthony Geraci, M.D is a Neurology healthcare provider based in Great Neck, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1871511238.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anthony Geraci, M.D has received a total of $468,969 in payments from pharmaceutical and medical device companies, with $554.10 received in 2022. These payments were reported across 333 transactions from 11 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($292,576).
As a Medicare-enrolled provider, Geraci has provided services to 1,138 Medicare beneficiaries, totaling 1,357 services with total Medicare billing of $139,127. Data is available for 4 years (2020–2023), covering 35 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Neurology, Neurology
- Location Great Neck, NY
- Active Since 07/17/2006
- Last Updated 06/16/2025
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1871511238
Products in Payments
- SPINRAZA (Biological) $317,921
- SOLIRIS (Drug) $38,200
- Soliris (Drug) $29,095
- ULTOMIRIS (Drug) $23,140
- FIRDAPSE (Drug) $11,998
- Non-Covered Product (Drug) $7,955
- ONPATTRO (Drug) $5,554
- DISEASE STATE (Drug) $2,975
- SOLIRIS (Biological) $510.00
- UBRELVY (Drug) $144.49
- SS White (Device) $29.57
- CHANTIX (Drug) $21.75
- QULIPTA (Drug) $17.47
- Radicava (Drug) $12.74
- GRALISE (Drug) $12.52
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Great Neck
Dr. Noah Rosen, M.d, M.D
Neurology — Payments: $323,580
Neurology $323,580
Robert Duarte, Md, MD
Neurology — Payments: $274,828
Neurology $274,828
Dr. Russell Surasky, D.o, D.O
Neurology — Payments: $171,591
Neurology $171,591
David Eidelberg, Md, MD
Neurology — Payments: $14,087
Neurology $14,087
Dr. Mark Gordon, Md, MD
Neurology — Payments: $10,466
Neurology $10,466
Peiyun Chu, Md, MD
Neurology — Payments: $9,757
Neurology $9,757